Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kJ/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A (Homo sapiens (Human)) | BDBM123686 (US8741907, 1) | PDB MMDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 5 | n/a | n/a | n/a | n/a | 7.5 | n/a |
Boehringer Ingelheim International GmbH US Patent | Assay Description The test substances are dissolved in 100% DMSO and serially diluted to determine their in vitro effect on PDE 9A. 2 uL portions of the diluted substa... | US Patent US8741907 (2014) BindingDB Entry DOI: 10.7270/Q21V5CNH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A (Homo sapiens (Human)) | BDBM123689 (US8741907, 6) | PDB MMDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 6 | n/a | n/a | n/a | n/a | 7.5 | n/a |
Boehringer Ingelheim International GmbH US Patent | Assay Description The test substances are dissolved in 100% DMSO and serially diluted to determine their in vitro effect on PDE 9A. 2 uL portions of the diluted substa... | US Patent US8741907 (2014) BindingDB Entry DOI: 10.7270/Q21V5CNH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tissue-type plasminogen activator (Homo sapiens (Human)) | BDBM298092 (3-[3-(2-tert-butoxyethyl)-1,2,4-oxadiazol-5-yl]-2-...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 6 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tissue-type plasminogen activator (Homo sapiens (Human)) | BDBM298254 (3-(2-methylbutanoyl)-7-(piperidin-4-yl)pyrazolo[1,...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 8 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tissue-type plasminogen activator (Homo sapiens (Human)) | BDBM298255 (3-(cyclopropylcarbonyl)-7-(piperidin-4-yl)pyrazolo...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 8 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tissue-type plasminogen activator (Homo sapiens (Human)) | BDBM298041 (3-(2-methyl-1,3-thiazol-5-yl)-7-(piperidin-4-yl)py...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 8.20 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tissue-type plasminogen activator (Homo sapiens (Human)) | BDBM297950 (7-(piperidin-4-yl)-3-{5-[4-(trifluoromethyl)phenyl...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 8.70 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tissue-type plasminogen activator (Homo sapiens (Human)) | BDBM298115 (7-(piperidin-4-yl)-3-(piperidin-1-ylcarbonyl)pyraz...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 9 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tissue-type plasminogen activator (Homo sapiens (Human)) | BDBM298123 (3-(4-cyclohexyl-1,3-thiazol-2-yl)-7-(piperidin-4-y...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 9 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tissue-type plasminogen activator (Homo sapiens (Human)) | BDBM298009 (3-[3-(4-fluorobenzyl)-1,2,4-oxadiazol-5-yl]-7-(pip...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 9.70 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290292 (2-Oxo-4-(piperidin-4-yl)-1,2-dihydropyrimido[1,2-b...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 10 | n/a | n/a | n/a | n/a | 7.0 | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall... | US Patent US10098883 (2018) BindingDB Entry DOI: 10.7270/Q2G73GSM | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tissue-type plasminogen activator (Homo sapiens (Human)) | BDBM298073 (3-[5-(2-phenylethyl)-1,3,4-oxadiazol-2-yl]-7-(pipe...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 10 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tissue-type plasminogen activator (Homo sapiens (Human)) | BDBM298184 (Rel-3-{5-[(1R,2S)-2-methylcyclopentyl]-1,2,4-oxadi...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 10 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tissue-type plasminogen activator (Homo sapiens (Human)) | BDBM298237 (3-[3-(2-methoxyphenyl)-1,2,4-oxadiazol-5-yl]-2-met...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 10 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tissue-type plasminogen activator (Homo sapiens (Human)) | BDBM298246 (3-[3-(4-hydroxybenzyl)-1,2,4-oxadiazol-5-yl]-2-met...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 10 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290292 (2-Oxo-4-(piperidin-4-yl)-1,2-dihydropyrimido[1,2-b...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 10 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10668071 (2020) BindingDB Entry DOI: 10.7270/Q2KP8554 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290334 (9-Fluoro-10-phenyl-4-(piperidin-4-yl)pyrimido[1,2-...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 11 | n/a | n/a | n/a | n/a | 7.0 | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall... | US Patent US10098883 (2018) BindingDB Entry DOI: 10.7270/Q2G73GSM | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290336 (10-Chloro-8-methyl-4-(piperidin-4-yl)pyrimido[1,2-...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 11 | n/a | n/a | n/a | n/a | 7.0 | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall... | US Patent US10098883 (2018) BindingDB Entry DOI: 10.7270/Q2G73GSM | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tissue-type plasminogen activator (Homo sapiens (Human)) | BDBM297845 (5-[5-Oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 11 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tissue-type plasminogen activator (Homo sapiens (Human)) | BDBM298063 (3-[5-(3-chlorobenzyl)-1,3,4-oxadiazol-2-yl]-7-(pip...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 11 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tissue-type plasminogen activator (Homo sapiens (Human)) | BDBM298096 (2-methyl-3-[3-(4-methylphenyl)-1,2,4-oxadiazol-5-y...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 11 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tissue-type plasminogen activator (Homo sapiens (Human)) | BDBM298098 (3-(4-ethyl-1,3-thiazol-2-yl)-7-(piperidin-4-yl)pyr...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 11 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tissue-type plasminogen activator (Homo sapiens (Human)) | BDBM298127 (3-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-2-methyl-7-(...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 11 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tissue-type plasminogen activator (Homo sapiens (Human)) | BDBM298161 (Cyclobutyl 2-methyl-5-oxo-7-(piperidin-4-yl)-4,5-d...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 11 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tissue-type plasminogen activator (Homo sapiens (Human)) | BDBM298170 (7-(piperidin-4-yl)-3-(1,2-thiazol-5-yl)pyrazolo[1,...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 11 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tissue-type plasminogen activator (Homo sapiens (Human)) | BDBM298253 (3-(cyclopentylcarbonyl)-7-(piperidin-4-yl)pyrazolo...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 11 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290334 (9-Fluoro-10-phenyl-4-(piperidin-4-yl)pyrimido[1,2-...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 11 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10668071 (2020) BindingDB Entry DOI: 10.7270/Q2KP8554 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290336 (10-Chloro-8-methyl-4-(piperidin-4-yl)pyrimido[1,2-...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 11 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10668071 (2020) BindingDB Entry DOI: 10.7270/Q2KP8554 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tissue-type plasminogen activator (Homo sapiens (Human)) | BDBM297791 (Ethyl 5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 11 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tissue-type plasminogen activator (Homo sapiens (Human)) | BDBM297809 (7-(Piperidin-4-yl)-3-(3-propyl-1,2,4-oxadiazol-5-y...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 12 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tissue-type plasminogen activator (Homo sapiens (Human)) | BDBM297842 ((−)-trans-7-(2-Methylpiperidin-4-yl)-5-oxo-4...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 12 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tissue-type plasminogen activator (Homo sapiens (Human)) | BDBM297850 (3-(Phenylsulfonyl)-7-(piperidin-4-yl)pyrazolo[1,5-...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 12 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tissue-type plasminogen activator (Homo sapiens (Human)) | BDBM298037 (3-{5-[4-methyl-2-(trifluoromethyl)phenyl]-1,2,4-ox...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 12 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tissue-type plasminogen activator (Homo sapiens (Human)) | BDBM298114 (3-[(3,3-difluoroazetidin-1-yl)carbonyl]-7-(piperid...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 12 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tissue-type plasminogen activator (Homo sapiens (Human)) | BDBM298238 (3-[3-(2-fluorophenyl)-1,2,4-oxadiazol-5-yl]-2-meth...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 12 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290286 (7-Bromo-4-(piperidin-4-yl)pyrido[4′,3′...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 13 | n/a | n/a | n/a | n/a | 7.0 | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall... | US Patent US10098883 (2018) BindingDB Entry DOI: 10.7270/Q2G73GSM | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290309 ((−)-trans-10-Ethoxy-4-(2-methylpiperidin-4-y...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 13 | n/a | n/a | n/a | n/a | 7.0 | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall... | US Patent US10098883 (2018) BindingDB Entry DOI: 10.7270/Q2G73GSM | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290314 (10-(2-Fluorophenyl)-4-(piperidin-4-yl)pyrimido[1,2...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 13 | n/a | n/a | n/a | n/a | 7.0 | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall... | US Patent US10098883 (2018) BindingDB Entry DOI: 10.7270/Q2G73GSM | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290320 (10-Cyclopentyl-4-(piperidin-4-yl)pyrimido[1,2-b]in...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 13 | n/a | n/a | n/a | n/a | 7.0 | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall... | US Patent US10098883 (2018) BindingDB Entry DOI: 10.7270/Q2G73GSM | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290324 (4-(Piperidin-4-yl)-10-[2-(trifluoromethyl)phenyl]p...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 13 | n/a | n/a | n/a | n/a | 7.0 | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall... | US Patent US10098883 (2018) BindingDB Entry DOI: 10.7270/Q2G73GSM | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tissue-type plasminogen activator (Homo sapiens (Human)) | BDBM297797 (N-Benzyl-5-oxo-7-(piperidin-4-yl)-4,5-dihydropyraz...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 13 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tissue-type plasminogen activator (Homo sapiens (Human)) | BDBM297808 (3-(3-Isopropyl-1,2,4-oxadiazol-5-yl)-7-(piperidin-...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 13 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tissue-type plasminogen activator (Homo sapiens (Human)) | BDBM297824 (4-[5-Oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 13 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tissue-type plasminogen activator (Homo sapiens (Human)) | BDBM297837 (3-(3-Methoxyphenyl)-7-(piperidin-4-yl)pyrazolo[1,5...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 13 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tissue-type plasminogen activator (Homo sapiens (Human)) | BDBM298061 (3-(5-methyl-4-phenyl-1,3-thiazol-2-yl)-7-(piperidi...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 13 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290286 (7-Bromo-4-(piperidin-4-yl)pyrido[4′,3′...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 13 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10668071 (2020) BindingDB Entry DOI: 10.7270/Q2KP8554 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290309 ((−)-trans-10-Ethoxy-4-(2-methylpiperidin-4-y...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 13 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10668071 (2020) BindingDB Entry DOI: 10.7270/Q2KP8554 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290314 (10-(2-Fluorophenyl)-4-(piperidin-4-yl)pyrimido[1,2...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 13 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10668071 (2020) BindingDB Entry DOI: 10.7270/Q2KP8554 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290320 (10-Cyclopentyl-4-(piperidin-4-yl)pyrimido[1,2-b]in...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 13 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10668071 (2020) BindingDB Entry DOI: 10.7270/Q2KP8554 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290324 (4-(Piperidin-4-yl)-10-[2-(trifluoromethyl)phenyl]p...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 13 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10668071 (2020) BindingDB Entry DOI: 10.7270/Q2KP8554 | |||||||||||
More data for this Ligand-Target Pair |
Displayed 1 to 50 (of 691 total ) | Next | Last >> |